Inhibikase Therapeutics Inc (IKT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.32 (+0.87%), Market cap $0.22B, 52-week low–high $1.41 ~ $2.14.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The comp
Financial statements, price targets, institutional (13F) holdings and related news for Inhibikase Therapeutics Inc are updated in real time on BlackAll Trade.
Inhibikase Therapeutics Inc trades at $2.32 (+0.87%). Real-time quotes and charts are available on BlackAll Trade.
Inhibikase Therapeutics Inc has a market cap of about $0.22B.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arteria